KemPharm (NASDAQ:KMPH) Stock Price Up 5%

KemPharm Inc (NASDAQ:KMPH) rose 5% during trading on Friday . The stock traded as high as $0.44 and last traded at $0.42, approximately 1,605,200 shares traded hands during trading. A decline of 40% from the average daily volume of 2,681,537 shares. The stock had previously closed at $0.40.

KMPH has been the subject of several research analyst reports. Zacks Investment Research downgraded KemPharm from a “buy” rating to a “hold” rating in a research note on Saturday, November 23rd. HC Wainwright reiterated a “buy” rating and set a $2.50 target price on shares of KemPharm in a research note on Thursday, December 19th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. KemPharm has a consensus rating of “Hold” and an average price target of $1.76.

The company has a 50 day moving average of $0.43 and a 200-day moving average of $0.79. The firm has a market capitalization of $13.91 million, a P/E ratio of -0.17 and a beta of 1.26.

KemPharm (NASDAQ:KMPH) last released its quarterly earnings results on Thursday, November 14th. The specialty pharmaceutical company reported $0.06 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.28) by $0.34. The firm had revenue of $11.46 million during the quarter. Equities analysts anticipate that KemPharm Inc will post -0.91 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Wedbush Securities Inc. boosted its stake in KemPharm by 738.5% in the 3rd quarter. Wedbush Securities Inc. now owns 97,430 shares of the specialty pharmaceutical company’s stock valued at $67,000 after purchasing an additional 85,810 shares during the period. BlackRock Inc. boosted its stake in KemPharm by 21.7% in the 2nd quarter. BlackRock Inc. now owns 106,490 shares of the specialty pharmaceutical company’s stock valued at $186,000 after purchasing an additional 19,001 shares during the period. RDA Financial Network boosted its stake in KemPharm by 801.9% in the 3rd quarter. RDA Financial Network now owns 158,109 shares of the specialty pharmaceutical company’s stock valued at $71,000 after purchasing an additional 140,578 shares during the period. Finally, Vanguard Group Inc. boosted its stake in KemPharm by 134.5% in the 2nd quarter. Vanguard Group Inc. now owns 1,337,571 shares of the specialty pharmaceutical company’s stock valued at $2,341,000 after purchasing an additional 767,100 shares during the period. Institutional investors and hedge funds own 25.79% of the company’s stock.

About KemPharm (NASDAQ:KMPH)

KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's product candidate includes KP415 and KP484 for the treatment of attention deficit hyperactivity disorder; and KP879 for the treatment of stimulant use disorder.

Read More: What is an Initial Coin Offering (ICO)?

Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.